ReviewBiomedicines2020
Current Advances in Pediatric Onset Multiple Sclerosis.
Review in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.Neurology · 2025Trial
- Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- Disproportionate pace of evidence-based care implementation in pediatric-onset multiple sclerosis: consequences and opportunities.Implementation science communications · 2026Article
- Adaptation of the Transition Readiness Assessment Questionnaire for Pediatric-Onset Multiple Sclerosis: Protocol for a User-Centered Design Approach.JMIR research protocols · 2026Article
- Early-Age Cuprizone Exposure Induces Region-Specific Demyelination and Neuroinflammation in Mice.Neuromolecular medicine · 2026Article
- Prevalence, Incidence, and Risk of Different Comorbidity Categories in Pediatric Multiple Sclerosis: A Systematic Review and Meta-Analysis Protocol.Children (Basel, Switzerland) · 2026Article
- Bodily experiences in multiple sclerosis: functional neurological symptoms, body image dissatisfaction, and disordered eating behaviors. A narrative review.Frontiers in psychology · 2026Review
- Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Age-Onset-Related Particularities of Pediatric MS-Understanding the Spectrum: A Tertiary Center Experience.Diseases (Basel, Switzerland) · 2025Article
- Optical coherence tomography and angiography reveal early retinal alterations in pediatric-onset multiple sclerosis.European journal of pediatrics · 2025Article
- Overtime Challenges of Diagnosis and Treatment in Two Pediatric Patients with Extensive Cerebral Tumefactive Lesions Indicative of Baló's Type Multiple Sclerosis.Children (Basel, Switzerland) · 2025Article
- Pediatric-Onset Multiple Sclerosis (POMS) and Epilepsy: Exploring Etiological Complexity-Outcomes from a Single-Center Experience.Children (Basel, Switzerland) · 2025Article
- Transitioning from pediatric to adult multiple sclerosis care: Challenges, strategies and therapy.Journal of pediatric rehabilitation medicine · 2025Review
- Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS).Immunity & ageing : I & A · 2024Review
- A case report of pediatric-onset MS associated uveitis.Journal of ophthalmic inflammation and infection · 2024Article
- Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: a narrative review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Review
- Parental Experiences in Pediatric Multiple Sclerosis: Insights from Quantitative Research.Children (Basel, Switzerland) · 2024Review
- Well-being among parents of youth with multiple sclerosis: a preliminary longitudinal study.Frontiers in psychology · 2024Article
- Pediatric Multiple Sclerosis: Changing the Trajectory of Progression.Current neurology and neuroscience reports · 2023Review
- Juvenile multiple sclerosis: addressing epidemiology, diagnosis, therapeutic, and prognostic updates along with cognitive dysfunction and quality of life.Annals of medicine and surgery (2012) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an autoimmune inflammatory disease affecting the central nervous system leading to demyelination. MS in the pediatric population is rare, but has been shown to lead to significant disability over the duration of the disease. As we have learned more about pediatric MS, there has been a development of improved diagnostic criteria leading to earlier diagnosis, earlier initiation of disease-modifying therapies (DMT), and an increasing number of DMT used in the treatment of pediatric MS. Over time, treatment with DMT has trended towards the initiation of higher efficacy treatment at time of diagnosis to help prevent further disease progression and accrual of disability over time, and there is evidence in current literature that supports this change in treatment patterns. In this review, we discuss the current knowledge in diagnosis, treatment, and clinical outcomes in pediatric MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.